Wearable Devices for Patient Monitoring in Long QT Syndrome
Launched by QUEEN MARY UNIVERSITY OF LONDON · Mar 14, 2025
Trial Information
Current as of May 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring the use of wearable devices to monitor patients with Long QT Syndrome, a heart condition that can cause irregular heartbeats. The main goal is to see if these devices can help keep track of patients' heart health and potentially alert them to any issues.
To participate in the study, you need to be at least 18 years old and have a confirmed diagnosis of Long QT Syndrome. You should also have a smartphone that runs on iOS version 15 or Android OS 9.0 or higher and be willing to give your consent to join the trial. The study is not yet recruiting participants, so if you're interested, keep an eye out for updates. Participants will likely be asked to wear a device that tracks their heart activity, helping researchers gather valuable information about managing this condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical diagnosis of Long QT Syndrome
- • Aged 18 years or over
- • Phone with iOS version 15 or Android OS 9.0 or higher
- • Able and willing to provide informed consent
- Exclusion Criteria:
- • Unwilling or unable to give consent
- • Ventricular pacing at recruitment
- • Bundle branch block or pre-excitation at baseline
About Queen Mary University Of London
Queen Mary University of London is a prestigious research-intensive institution recognized for its commitment to advancing medical science and improving health outcomes. As a leading sponsor of clinical trials, the university harnesses its academic excellence and innovative research capabilities to explore groundbreaking treatments and therapies across various medical disciplines. With a focus on collaboration, the institution engages with a diverse network of clinicians, researchers, and industry partners to ensure rigorous study design, ethical conduct, and the translation of research findings into clinical practice. Queen Mary University of London is dedicated to contributing to the global body of knowledge in healthcare through high-quality clinical research that prioritizes patient safety and welfare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
William J Young, MBBS, PhD
Principal Investigator
Queen Mary University of London and St Bartholomew's Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported